Story perspectives

Regeneron Invests $119.5M to Boost DNA Research

1/14/2025

50 10

Summary

Story summary

Regeneron Pharmaceuticals is making a bold move by investing $119.5 million in Truveta to supercharge its DNA-linked healthcare database through the Truveta Genome Project. This groundbreaking initiative seeks to sequence the DNA of 10 million more de-identified patients, paving the way for revolutionary advancements in genetic research and drug discovery. Illumina joins the mission with a $20 million contribution, amplifying the impact of this vital work.

1 of 1

Story summary

Regeneron Pharmaceuticals is making a bold move by investing $119.5 million in Truveta to supercharge its DNA-linked healthcare database through the Truveta Genome Project. This groundbreaking initiative seeks to sequence the DNA of 10 million more de-identified patients, paving the way for revolutionary advancements in genetic research and drug discovery. Illumina joins the mission with a $20 million contribution, amplifying the impact of this vital work.